Search results
Results from the WOW.Com Content Network
(Reuters) -Shares of Grail fell as much as 13.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina. The stock traded as low as $15.84 after opening at $18. ...
The blood test, called Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for that result in cancer deaths, Grail CEO Bob Ragu
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms. [ 3 ]
Meanwhile, after researching the issue of Illumina’s controversial acquisition of Grail, I think that there’s an 80%-90% chance that the deal will be approved. Illumina Stock Will Be ...
Grail uses Illumina sequencing technology for tests. [26] Grail planned to roll out the tests by 2019. [27] In September 2020, Illumina announced a proposed cash and stock deal to acquire Grail for $8 billion. [28] [29] In November 2018, Illumina proposed the acquisition of Pacific Biosciences for $8.00 per share or around $1.2 billion in total.
In June 2024, news emerged that some Grail investors had initiated a class action lawsuit claiming the company exaggerated the Galleri test's potential impact. [ 2 ] This lawsuit is also vaguely referred to in the lead, which strikes me as WP:UNDUE given the passing nature of the mention in the source (and the paucity of other major coverage).
Illumina, which founded Grail and spun it off in 2016 only to re-acquire it in 2021 for $7.1 billion, had fought against the European Commission's decision to wield a rarely-used power called ...
The Dow jumped 700 points and the Nasdaq gained more than 2% as investors cheered encouraging inflation data and a strong start to earnings season.